https://electra-therapeutics.com/publication/2025-ash-the-surpass-trial-a-phase-2-3-registrational-trial-of-ela026-in-subjects-with-treatment-naive-secondary-hemophagocytic-lymphohistiocytosis/2026-05-14T12:10:36-04:00https://electra-therapeutics.com/publication/2025-ash-survival-outcomes-of-patients-with-secondary-hemophagocytic-lymphohistiocytosis-at-two-academic-medical-centers-in-the-united-states/2026-05-15T12:40:48-04:00https://electra-therapeutics.com/publication/2024-ash-ela026-a-monoclonal-antibody-targeting-signal-regulatory-protein-%ce%b1-%ce%b21-%ce%b3-rapidly-controls-inflammation-and-improves-2-month-survival-in-treatment-naive-malignancy-associated/2026-05-15T15:01:50-04:00https://electra-therapeutics.com/publication/2024-eha-late-breaker-ela026-targeting-of-sirp-immune-cells-results-in-a-high-response-rate-and-improved-2-month-survival-of-treatment-naive-malignancy-associated-hemophagocytic-lymphohistiocytos/2026-05-12T18:10:48-04:00https://electra-therapeutics.com/publication/characterization-of-ela026-a-clinical-stage-monoclonal-antibody-that-rapidly-and-potently-depletes-myeloid-cells-and-t-lymphocytes/2026-05-15T12:40:29-04:00